AI financing stress, storage/optics pricing power, Middle East oil risk and the Moderna data debate set the tape. Tech is selling off on capex returns even as WDC and MaxLinear print strong AI-linked growth; Brent is above $113; Moderna's selloff is being argued as expectations, not failed data.
A global tech selloff deepened even as AI demand stayed sold out: SK Hynix scrapped Solidigm's US IPO, SpaceX was finalizing $40bn of debt at sharply higher yields, and Oracle bonds yield near 9%. Bulls point to contracted capacity; bears to cash flow and borrowing costs. The mispricing is in financed capacity, not model demand.
Western Digital lifted revenue 55% on 22% exabyte growth while price per terabyte rose 28% and gross margin hit 58.1%; MaxLinear's optical revenue guide rose to $250-270m with 1.6T DSP pricing doubling. Both stocks still sold off. The debate is whether scarcity rents persist into 2028 or invite substitution and customer pushback; HDD and optical component suppliers are the cleaner read-through than storage buyers.
Brent rose 4% to $113.17 after deadly strikes on Saudi targets, including an Aramco site and Dammam airport; Aramco told Dhahran staff to work remotely. Hormuz flows have normalized, so the premium is anticipatory, not physical shortage. Diesel and tanker rates carry the sharper stress, with US oil exports to Asia falling. The risk is a wider Iran-US confrontation after the midterms.
Mizuho's Jared Holz argued the post-data selloff reflected a high valuation bar, not weak cancer-vaccine efficacy, and called Merck the better platform exposure. A Reddit clinical thread countered that Phase 3 distant-metastasis-free-survival hazard ratio worsened to 0.62 from 0.34 in Phase 2, a more meaningful efficacy signal. Both can be true: expectations were inflated, and the data are less clean than bulls claim.
Retail buyers added BE on the post-earnings dip; one poster loaded up at $203 after the company beat and raised guidance, while Grant Beaty said he remains long a small position despite disclosure concerns.
One retail trader bought CRWV at $55 explicitly against calls for zero, while another refused to sell a losing position; this is a contrarian equity bid even as a bankruptcy debate intensifies.
A retail account disclosed 27,665 QS shares at $4.374, betting Q3 commercialization progress and a November 11 catalyst can re-rate the stock.
Mizuho's Jared Holz prefers Merck over Moderna for cancer-vaccine exposure and would wait for an AbbVie pullback after healthcare's fund-flow rally; he is cautious on healthcare broadly into earnings.
Bubbleboi is not buying ASML now and doubts High-NA will be used on most layers, while flagging ASML/Besi collaboration on die-stress programs as the part worth watching.
Noble called CoreWeave a short on serious bankruptcy risk and rejected Tesla's robotics valuation, while David Lin flagged AI infrastructure capex returns and Oracle's financing risk.
Temple Eight expects a Nasdaq bear market with a 50% drawdown, says oil above $100 caps tech, and calls short copper a catch-up trade to AI downside.